To prevent delayed nausea and vomiting associated with initial/repeat courses of emetogenic cancer chemotherapy (to be used with dexamethasone and a 5–HT3 antagonist).
Acts as a selective antagonist at substance P/neurokinin 1 (NK1 ) receptors in the brain.
- Decreased nausea and vomiting associated with chemotherapy.
- Augments the antiemetic effects of dexamethasone and 5-HT3 antagonists.
Absorption: Well absorbed following oral administration.
Distribution: Extensively distributed to tissues.
Protein Binding: 99.8%
Metabolism and Excretion: Mostly metabolized, primarily by CYP3A4; one metabolite, C4–pyrrolidine-hydroxylated rolapitant (M19) has antiemetic activity. Excretion is mainly via hepato/biliary elimination. 14% excreted in urine (8% as metabolites), 73% in feces (38% as unchanged drug).
Half-life: Rolapitant– 7 days; M19– 7 days.
TIME/ACTION PROFILE (blood levels)
|PO||within 30 min||4 hr||unknown|
- Concurrent use of CYP2D6 substrates with a narrow therapeutic index.
Use Cautiously in:
- Concurrent use of other CYP2D6 substrates;
- Severe hepatic impairment (avoid if possible; if unavoidable, monitor carefully);
- OB: Safety not established;
- Lactation: Weigh maternal benefits against risks to the infant;
- Pedi: Safety and effectiveness not established;
- Geri: May be more sensitive to drug effects.
Adverse Reactions/Side Effects
GI: abdominal pain, ↓ appetite, dyspepsia, hiccups, stomatitis
GU: ↓ fertility (females)
Hemat: anemia, neutropenia
Misc: infusion reactions
* CAPITALS indicate life-threatening.
Underline indicate most frequent.
- ↑ levels and risk of serious cardiac toxicity with CYP2D6 substrates with a narrow therapeutic index, including thioridazine and pimozide ; concurrent use contraindicated.
- May ↑ levels and risk of toxicity of other CYP2D6 substrates for an extended period of time (≥28 days).
- May ↑ levels and risk of toxicity of Breast-Cancer-Resistance Protein (BCRP) substrates, includingirinotecan, methotrexate, rosuvastatin and topotecan ; dose reduction may be necessary.
- May ↑ levels and risk of toxicity of P-glycoprotein substrates, including digoxin ; avoid concurrent use with P-gp substrates with a narrow therapeutic index.
- Strong CYP3A4 inducers, including rifampin , ↓ levels and effectiveness; avoid concurrent use.
PO (Adults) 180 mg within 2 hr prior to start of chemotherapy.
Tablets: 90 mg
- Assess nausea, vomiting, appetite, bowel sounds, and abdominal pain prior to and following administration.
Lab Test Considerations:
May cause ↓ WBC.
- PO Administer 2 hr before starting chemotherapy without regard to food. Due to long action, administered no more frequently than once every 14 days. Given with dexamethasone and a 5-HT3 antagonist.
- Intermittent Infusion: Administer 2 hr before starting chemotherapy. Solution is translucent white and does not need to be shaken; do not inject solutions that are discolored or contain particulate matter. Insert a vented IV set through septum of vial and use immediately; do not dilute. Infuse through a Y-site of 0.9% NaCl. D5W, D5/LR, or LR.
- Rate: Infuse over 30 min.
- Instruct patient to take rolapitant as directed. Direct patient to read the Patient Package Insert before starting therapy and each time Rx renewed in case of changes.
- Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and consult health care professional before taking any new medications.
- Advise patient and family to use general measures to decrease nausea (begin with sips of liquids and small, nongreasy meals; provide oral hygiene; remove noxious stimuli from environment).
- Advise patient to notify health care professional if pregnancy is planned or suspected, or if breast feeding.
Decreased delayed nausea and vomiting associated with emetogenic chemotherapy.
The Washington Manual of Medical Therapeutics helps you diagnose and treat hundreds of medical conditions. Consult clinical recommendations from a resource that has been trusted on the wards for 50+ years. Complete Product Information.